Sanctuary Advisors LLC raised its holdings in Natera, Inc. (NASDAQ:NTRA – Free Report) by 12.1% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,820 shares of the medical research company’s stock after buying an additional 1,917 shares during the period. Sanctuary Advisors LLC’s holdings in Natera were worth $3,564,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Coatue Management LLC increased its holdings in shares of Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after acquiring an additional 2,463,008 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares during the period. Norges Bank bought a new position in shares of Natera in the fourth quarter valued at about $372,398,000. JPMorgan Chase & Co. lifted its stake in shares of Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after buying an additional 1,225,420 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Natera by 39.0% during the 3rd quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock worth $386,338,000 after buying an additional 673,315 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of brokerages recently commented on NTRA. Royal Bank Of Canada assumed coverage on shares of Natera in a research note on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price target on the stock. Barclays cut their price objective on shares of Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research report on Wednesday, June 24th. Canaccord Genuity Group upped their target price on Natera from $285.00 to $330.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. TD Cowen reiterated a “buy” rating on shares of Natera in a research note on Wednesday. Finally, Wells Fargo & Company lifted their price target on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $267.83.
Insider Buying and Selling at Natera
In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $272.90, for a total transaction of $818,700.00. Following the transaction, the insider owned 134,643 shares in the company, valued at $36,744,074.70. This trade represents a 2.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Herm Rosenman sold 16,530 shares of Natera stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the transaction, the director directly owned 4,250 shares of the company’s stock, valued at $1,062,500. This represents a 79.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 178,872 shares of company stock valued at $39,627,696 over the last ninety days. 5.05% of the stock is owned by corporate insiders.
Natera Stock Performance
Shares of NTRA opened at $271.39 on Monday. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $288.04. The firm’s 50 day moving average is $233.97 and its 200-day moving average is $220.33. The stock has a market capitalization of $38.87 billion, a PE ratio of -166.50 and a beta of 1.51.
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
- Five stocks we like better than Natera
- Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
- Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises
- 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
